En Es
Categories

Industry News


Nova Biomedical Launches New Laboratory Blood Glucose Reference Analyzer

By Labmedica International staff writers
19 Nov 2020

Image: Nova Primary analyzer (Photo courtesy of Nova Biomedical)Nova Biomedical (Waltham, MA, USA) has launched Nova Primary, a rapid, accurate, easy to use, blood glucose laboratory analyzer that fills the need for a new glucose reference analyzer to replace the YSI STAT PLUS 2300 Glucose and L-Lactate analyzer from YSI, Inc., (Yellow Springs, OH, USA).

Manufacturers of blood glucose measuring devices and clinical diabetes researchers have relied on the YSI 2300 as a reference and correlation analyzer. However, as of July 2021, YSI, Inc. is no longer supporting the analyzer, and its discontinuation has left a critical industry void. The Nova Primary analyzer fills that need and will be available for sale in CE regulated countries from January 2021. The Nova Primary was also submitted to the US Food and Drug Administration (FDA) for 510(k) clearance in November 2020 and is anticipated to receive clearance in the first half of 2021.

Similar to the YSI 2300, Nova Primary uses a single, reusable glucose electrochemical sensor based on glucose oxidase and has a measurement range of 10-900 mg/dL. It uses a small, 25 microliter venous whole blood or plasma sample which is internally diluted like the YSI. Results are available in approximately two minutes. Nova Primary’s large color touchscreen display and intuitive, icon-based graphical user interface make it very straightforward to use. A single calibrator pack uses RFID data management to monitor the pack expiration date and number of samples remaining, eliminating the need for separate reagent bottles and daily monitoring of their levels. In clinical laboratory studies using venous whole blood and plasma Nova Primary demonstrated excellent correlation to the YSI 2300 and is traceable to NIST glucose standards.




E-mail Print
FaceBook Twitter Google+ Linked in

Nova Biomedical

Nova is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers. Nova’s biosensor technology is incorporated into products ranging from handheld meters for self- and point-of-care testing to critical care whole blood analyzers designed for rapid measurement of over 20 analytes.
Gold member
More info

More articles about Nova Biomedical

31 Oct 2022
Nova Primary Blood Glucose Reference Analyzer Receives US FDA Clearance
Nova Biomedical (Waltham, MA, USA) has received clearance from the U.S. Food and Drug Administration (FDA) for its Nova Primary as a blood glucose reference analyzer.
Read More
25 Jan 2021
Nova Biomedical Adds Sample Retain Collector to BioProfile FLEX2 Cell Culture Analyzer
Nova Biomedical (Waltham, MA, USA) has added a Sample Retain Collector (SRC) for its BioProfile FLEX2 automated cell culture analyzer which measures up to 16 tests including pH, gases, metabolites, osmolality, cell density, and cell viability.
Read More
20 Apr 2020
Nova's Stat EMS Basic Blood Testing System Launched in CE Mark Countries
Nova Biomedical (Waltham, MA, USA) has launched the Stat EMS Basic blood testing system for ambulance and emergency care in CE mark countries. Stat EMS Basic measures fingerstick capillary lactate, glucose, ketone, hemoglobin, and hematocrit in six to 40 seconds with laboratory-quality results.
Read More
20 Apr 2020
Nova's Stat Profile Prime Plus Blood Gas Analyzer Receives FDA Clearance for POC Use
Nova Biomedical (Waltham, MA, USA) has secured clearance from the US Food and Drug Administration (FDA) for its Stat Profile Prime Plus critical care blood gas analyzer for point-of-care (POC) use.
Read More
08 Apr 2020
Nova Biomedical Adds PT/INR Test to Allegro Analyzer for POC Testing
Nova Biomedical (Waltham, MA, USA) has added PT/INR testing for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. With the ability to test for clotting disorders and monitor the effectiveness of blood-thinning medications, the Allegro and its StatStrip-A companion meter provide 18 clinically important tests to help physicians make therapeutic decisions and adjustments at the POC.
Read More
03 Jan 2020
Nova Biomedical Launches New BioProfile FLEX2 On-Line Autosampler
 Nova Biomedical (Waltham, MA, USA) has launched the BioProfile FLEX2 On-Line Autosampler (OLS), a modular system that connects as many as 10 bioreactors to one FLEX2 analyzer for up to three weeks of walkaway, automated sampling, analysis, and feedback control of key cell culture analytes. The FLEX2 measures up to 16 tests, including pH, gases, metabolites, osmolality, cell density, and cell viability.
Read More

Additional news

23 Nov 2022
Global Visualization Instruments for MIS Market Driven by Increasing Demand for Endoscopy Procedures
The increasing demand for visualization systems for complex surgical procedures, growing demand for minimally invasive surgeries, and rising prevalence of chronic diseases are expected to help the global visualization instruments for minimally invasive surgery (MIS) market register a CAGR of 7.2% between 2022 and 2031 and reach a value of USD 21 billion by 2031.
Read More
11 Nov 2022
Global Diagnostic ECG Market Driven by Increased Incidence of Cardiac Diseases
The rising prevalence of such chronic conditions is necessitating the need for diagnosis and treatment in order to keep track of the patient's daily medical condition and maintain medical records. This, coupled with rising hospitalization of the older population for the treatment of cardiac diseases, has increased the need for electrocardiograph (ECG) diagnosis.
Read More
11 Nov 2022
Radcal to Supply Quality Assurance X-Ray Testing Equipment to West Physics
Radcal Corporation (Monrovia, CA, USA), a leading manufacturer of diagnostic X-ray quality assurance (QA) meters, has reached an agreement with West Physics (Atlanta, GA, USA), one of the largest and most successful Medical Physics groups in the U.S., to supply QA X-ray testing equipment.
Read More
09 Nov 2022
Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling
Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining panels, tissue staining, and imaging and analysis services.
Read More
08 Nov 2022
Global Infusion Pumps Market Driven by Increasing Incidence of Chronic Diseases
Rising demand for ambulatory infusion pumps in home care, increasing incidence of chronic diseases along with a rapid growth of the geriatric population, and growing number of surgical procedures being performed, are driving the growth of the global infusion pumps market. As a result, the market is projected to register a CAGR of 7% from USD 14.7 billion in 2022 to USD 20.5 billion by 2027.
Read More
07 Nov 2022
Mast Group Enters into Multi-Country Distribution Agreement for Nanomix's eLab System
Mast Group Limited (Liverpool, UK) and Nanomix (Emeryville, CA, USA) have entered into a multi-region distribution agreement wherein Mast will market and distribute the Nan?mix eLab system in the UK, Germany, France, Ireland and South Africa.
Read More
07 Nov 2022
AI-Enabled Diagnostic Testing Could Become More Accurate and Reliable than Current Tests
An expanded collaboration between two industry leaders will pave the way for the development of AI-enabled diagnostic testing that is more accurate and reliable than current U.S. tests for patients with chronic diseases, including kidney, cardiovascular, liver and neurologic conditions.
Read More
01 Nov 2022
Global Infectious Respiratory Disease Diagnostics Market Driven by New Multiplex PCR Tests and POC Products
The global infectious respiratory disease diagnostics market size is expected to reach USD 43.6 billion by 2030, driven by an increase in the prevalence of infectious respiratory diseases and initiatives taken by governments & non-profit organizations to introduce novel & innovative products to address the growing demand.
Read More
01 Nov 2022
Johnson & Johnson to Acquire Cardiovascular Technology Company Abiomed in USD 16.6 Billion Deal
Johnson & Johnson (New Brunswick, N.J., USA) has entered into a definitive agreement to acquire all outstanding shares of Abiomed, Inc. (Danvers, MA, USA) in a deal valued at approximately USD 16.6 billion which includes cash acquired.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions